MedTrace Logo

Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer

NCT03688204 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 118

Last updated 2022-03-07

No results posted yet for this study

Summary

This study aims to assess how a polygenic risk score (PRS) reported with the results of multi-gene panel testing affects the breast cancer risk management recommendations healthcare providers make to their patients. The PRS is a score based on small genetic changes, clinical history, and family history. The PRS is used to estimate remaining lifetime risk of developing breast cancer for patients with no personal history of breast cancer and an overall negative result from MGPT.

Conditions

  • Breast Cancer Risk

Sponsors & Collaborators

  • Ambry Genetics

    lead INDUSTRY

Principal Investigators

  • Brigette Tippin-Davis, PhD · Ambry Genetics

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-21
Primary Completion
2020-11-11
Completion
2020-11-11

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03688204 on ClinicalTrials.gov